These extremely rare tumors destroy joints, have a high recurrence rate, and while benign, have potential for metastasizing.
For decades, dermatologists have used their eyes, along with a magnifier called a dermatoscope, to try to distinguish abnormal but benign lesions from potential melanoma in order to avoid unneeded biopsies.
Although this tumor is benign, with no potential for metastasis, it has a tendency to exhibit local recurrence [2, 4 6].
Bosniak category I and II lesions are predicted to be benign, category III potential malignant and IV predominantly malignant.
According to World Health Organization (WHO) criteria, ovarian tumors can be classified as benign, low malignant potential (borderline), or malignant [ 4].
They represent a spectrum of neoplasms of widely different malignant potential: benign mucinous cystadenomas (Fig. 2); borderline tumors with malignant potential, or malignant (carcinoma in situ or invasive carcinoma).
Pancreatic endocrine tumors are classified as benign, uncertain malignant potential, and malignant on the basis of size, the presence or absence of lymphovascular invasion, and the number of mitoses and Ki-67 positive Ki-67 positiveohistocellsstry.
Ovarian neoplasms occur in benign, low malignant potential (LMP) and malignant forms although the relationship between these forms is not clear, nor are the genetic and biological events that underlie the initiation and progression of ovarian adenocarcinomas.
To identify genes associated with neoplastic progression in the serous subtype of ovarian tumors, we compared gene expression in tissues that exhibited the spectrum of tumor behavior, namely benign, low malignant potential (LMP) and invasive.
Our data confirm the importance of using a mixture of histologic and immunohistochemical parameters in order to predict potential benign or malignant behavior in a given GIST at diagnosis.
